Monday, December 08, 2025 | 01:36 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Serum Institute gets SEC thumbs up; Bharat Biotech proposal being discussed

US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
premium

This would be a restricted emergency use authorisation with some conditions

Sohini Das Mumbai
The expert panel that is advising the Drug Controller General of India (DCGI) on Covid-19 vaccines has given an in-principle nod today to the AstraZeneca-Oxford vaccine candidate, which Pune's Serum Institute of India will make and market here, say sources in the know. 

"Serum Institute's Covishield vaccine candidate has been given an in-principle nod from the expert panel and now the drug regulator needs to approve it. This would be a restricted emergency use authorisation with some conditions," said the source. 


While